TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37609778
Drug: Breast-conserving surgery
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast-conserving surgery and endocrine therapy (no other systemic therapy)
Study: 37610332
Drug: Nurse-led package
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-led package of care (non-pharmacological treatment)
Study: 37611121
Drug: Divarasib (GDC-6036)
Normalized name: calcium carbonate
DrugBank: Divarasib (DB17488)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divarasib (GDC-6036) administered orally once daily at doses ranging from 50 to 400 mg
Study: 37611156
Drug: Busulfan 80
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan 80 mg/m2 as outpatients on days -20 and -13 before transplant, Fludarabine 40 mg/m2 on days -6 to -3, busulfan dosed to achieve a target AUC of 20,000 mol/min for the whole course.
Study: 37611174
Drug: ASICA app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ASICA app for monthly total-skin self-examinations (TSSE)
Study: 37611246
Drug: Berberine 500
Normalized name: berberine
DrugBank: Berberine (DB04115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berberine 500 mg TID for 20 weeks
Study: 37612102
Drug: Oral supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplementation for patients with severe vitamin C depletion
Study: 37612114
Drug: Dual hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dual hormone fully closed loop (DHFCL)
Study: 37612114
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (HCL or treatment with multiple daily insulin injections + FGM/CGM)
Study: 37612115
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg CBN
Study: 37612115
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg CBN
Study: 37612300
Drug: mRNA-1273.214 (50-µg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273.214 (50-µg)
Study: 37612300
Drug: mRNA-1273 (50-µg)
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 (50-µg)
Study: 37612310
Drug: SARS-CoV-2 immunity
Normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 immunity after two vaccine doses
Study: 37612608
Drug: IPF patients
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPF patients with antifibrotic therapy at enrolment
Study: 37612610
Drug: Biopsy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biopsy combined with same-session MR-guided LITT therapy followed by CRT
Study: 37612621
Drug: Biweekly single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biweekly single-dose actinomycin D (1.25 mg/m² IV pulse)
Study: 37612621
Drug: Multiday methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Multiday methotrexate therapy
Study: 37612698
Drug: Take home
Normalized name: Sodium Fluoride 5 mg in 1 g DENTAL GEL, DENTIFRICE [Take Home Fluoride Cool Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take home naloxone (THN) from participating harm reduction and drug treatment sites
Study: 37614541
Drug: Tafolecimab 450
Normalized name: Tafolecimab
DrugBank: Tafolecimab (DB16336)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafolecimab 450 mg every 4 weeks (Q4W)
Study: 37614821
Drug: Intracerebroventricular CLN5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracerebroventricular CLN5 gene therapy
Study: 37614943
Drug: Ticagrelor monotherapy
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor monotherapy after 3 months of DAPT
Study: 37615485
Drug: Carboplatin-based chemotherapy
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin-based chemotherapy alone
Study: 37615836
Drug: Nemolizumab (drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemolizumab (drug treatment)
Study: 37615989
Drug: TLC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLC with MTM (intensive telephone coaching and combination nicotine replacement therapy for 1 year with at least monthly contact, plus pharmacist-referral for prescription medications)
Study: 37615989
Drug: TLC (intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLC (intensive telephone coaching and combination nicotine replacement therapy for 1 year with at least monthly contact)
Study: 37616221
Drug: Trivalent Influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent Influenza HA vaccine (TIV)
Study: 37616289
Drug: A7+TouchCare insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: A7+TouchCare insulin patch pump system
Study: 37616289
Drug: Omnipod insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omnipod insulin pump system
Study: 37616301
Drug: Moxidectin (MOX)
DrugBank: Moxidectin (DB11431)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxidectin (MOX) 8 mg plus DEC and ALB
Study: 37616301
Drug: Ivermectin (IVM)
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin (IVM) 0.2 mg/kg plus DEC 6 mg/kg and ALB 400 mg
Study: 37616583
Drug: Fully closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fully closed-loop with ultrarapid insulin lispro (CamAPS HX system)
Study: 37616583
Drug: Insulin pump
Normalized name: insulin pump syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin pump therapy with continuous glucose monitoring (CGM)
Study: 37619579
Drug: Adjuvant oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant oral mitotane (two or three times daily, target plasma concentration of 14-20 mg/L) for 2 years
Study: 37619579
Drug: Adjuvant oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant oral mitotane
Study: 37619584
Drug: IBIO123 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBIO123 (1 mg, 5 mg, or 10 mg)
Study: 37619584
Drug: IBIO123 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBIO123 (10 mg)
Study: 37619705
Drug: Acetaminophen and
Normalized name: Acetaminophen and Aspirin Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen and hydrocodone
Study: 37619980
Drug: SGN-B6A (antibody-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGN-B6A (antibody-drug conjugate directed to integrin beta-6)
Study: 37620260
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of argipressin
Study: 37620270
Drug: Automated clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated clinical decision support tool for intraoperative insulin dosing
Study: 37620270
Drug: Standard insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard insulin administration (control)
Study: 37620294
Drug: High-carbohydrate fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-carbohydrate fluid diet (CFD) - 400 mL of maltodextrin orally 2 h before ERCP
Study: 37620508
Drug: EGCG solution
Normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG solution (epigallocatechin-3-gallate)
Study: 37620855
Drug: Drug Resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Resistance Mutation (DRM) testing
Study: 37620929
Drug: SMART intervention
Normalized name: benzalkonium chloride Topical Foam [Smart San]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMART intervention (twice weekly football, martial arts, and dance coaching)
Study: 37621674
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 mg/kg daily for 7 days, followed by 5 mg/kg daily for 7 days)
Study: 37621674
Drug: Azithromycin among
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin among participants receiving other antibiotics
Study: 37621674
Drug: Azithromycin among
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin among antibiotic-naïve participants
Study: 37621688
Drug: Lapatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib plus capecitabine (L+C)
Study: 37622035
Drug: Fluvoxamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (50 mg on day 1, 100 mg twice daily thereafter for 15 days)
Study: 37622681
Drug: Semaglutide (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide (2.4 mg)
Study: 37622738
Drug: Belantamab mafodotin
Normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Belantamab mafodotin 2.5 mg/kg every 3 weeks
Study: 37622738
Drug: Belantamab mafodotin
Normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Belantamab mafodotin 3.4 mg/kg every 3 weeks
Study: 37622738
Drug: Belantamab mafodotin
Normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Belantamab mafodotin (both doses)
Study: 37623007
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 24 months of ADT, PBRT, and PLNRT
Study: 37623203
Drug: Green coconut
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green coconut water (330 mL)
Study: 37623203
Drug: Dark chocolate
Normalized name: Ensure Original Dark Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dark chocolate (35 g of 70% dark chocolate)
Study: 37623205
Drug: Intensive behavioral
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive behavioral treatment intervention (IC)
Study: 37623329
Drug: 0.05 mmol/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mmol/kg gadobutrol (half dose)
Study: 37623329
Drug: 0.1 mmol/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mmol/kg gadobutrol (single dose)
Study: 37624619
Drug: Pirtobrutinib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirtobrutinib monotherapy (200 mg once daily)
Study: 37624900
Drug: Graded Exposure
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded Exposure Treatment (GET Living)
Study: 37624901
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus intervention (pain coping skills training and optional support for opioid taper)
Study: 37625235
Drug: Atezolizumab 1200
Normalized name: atezolizumab 1200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 1200 mg every 3 weeks for 22 cycles with platinum-based chemotherapy and bevacizumab
Study: 37625235
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with platinum-based chemotherapy and bevacizumab
Study: 37625518
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg JNJ-10450232 (NTM-006)
Study: 37625518
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg JNJ-10450232 (NTM-006)
Study: 37625526
Drug: Highest quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest quartile of HOMA-IR (indicating higher insulin resistance)
Study: 37625587
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose esomeprazole (80 mg bolus followed by 12 mg/h for 72 h and a second 80 mg bolus 12 h after the first one)
Study: 37625587
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose esomeprazole
Study: 37625814
Drug: TQB2450 (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2450 (1200 mg every 3 weeks) and anlotinib (10 mg or 12 mg once daily, 2-week on/1-week off)
Study: 37626367
Drug: Camrelizumab combined
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Camrelizumab combined with radiotherapy as neoadjuvant therapy
Study: 37629366
Drug: No-CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-CPAP treatment (control)
Study: 37629638
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of a class I pullulan-based medical device, applied two times daily.
Study: 37629671
Drug: Intramuscular Electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular Electrical Stimulation
Study: 37631885
Drug: Ad26.ZEBOV, MVA-BN-Filo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen (two doses with a 56-day interval)
Study: 37632201
Drug: Zibotentan 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zibotentan 0.25 mg/dapagliflozin 10 mg QD
Study: 37632201
Drug: Zibotentan 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zibotentan 1.5 mg/dapagliflozin 10 mg QD
Study: 37632201
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg QD alone
Study: 37632240
Drug: Epinephrine/adrenaline injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine/adrenaline injection
Study: 37632240
Drug: Auto-injector prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auto-injector prescription
Study: 37632455
Drug: Outpatient oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient oral diuretic intensification
Study: 37632455
Drug: Expanded composite
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Expanded composite end point (cardiovascular death, HF hospitalization, urgent HF visit, or outpatient oral diuretic intensification)
Study: 37632469
Drug: Alirocumab (PCSK9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab (PCSK9 inhibitor)
Study: 37632592
Drug: Carfilzomib (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib (10, 15, or 20 mg/m2) in combination with R-ICE (rituximab, ifosfamide, carboplatin, etoposide)
Study: 37632656
Drug: 24-hour/day foslevodopa/foscarbidopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour/day foslevodopa/foscarbidopa CSCI at individually optimized therapeutic doses (approximately 700-4250 mg of LD per 24 hours)
Study: 37632942
Drug: ASICA intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASICA intervention (digital health care intervention providing monthly prompts for TSSE and access to a dermatology nurse)
Study: 37633156
Drug: Venetoclax 100
Normalized name: venetoclax 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax 100 mg daily from days 1-21, Itraconazole 100 mg twice daily from days 1-21, Azacitidine 100 mg subcutaneously once daily from days 1-7
Study: 37633275
Drug: Intermediate MRG-001
Normalized name: neurospora intermedia allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate MRG-001 dose
Study: 37633589
Drug: LNG 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG 52 mg IUD
Study: 37634135
Drug: Catheter ablation
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter ablation and guideline-directed medical therapy
Study: 37634145
Drug: ECLS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECLS plus usual medical treatment
Study: 37634145
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual medical treatment alone)
Study: 37634234
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (DXM20)
Study: 37634234
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care 6 mg dose of dexamethasone (DXMSoC)
Study: 37634517
Drug: Immediate isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate isoniazid preventive therapy (28 weeks isoniazid [300 mg daily], then placebo until week 40 after delivery)
Study: 37634517
Drug: Deferred treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred treatment (placebo until week 12 after delivery, then isoniazid [300 mg daily] for 28 weeks)
Study: 37634517
Drug: Immediate isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate isoniazid preventive therapy
Study: 37634629
Drug: anti-PD-1 inhibitor
Normalized name: anti-inhibitor coagulant complex 1 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-PD-1 inhibitor in combination with standard systemic treatment
Study: 37634655
Drug: Anti-factor Xa
Normalized name: Innohep, 20,000 anti-Factor Xa intl units/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-factor Xa NOAC (apixaban 5 mg twice per day, edoxaban 60 mg daily, or rivaroxaban 20 mg daily for 12 months)
Study: 37634655
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid 75 mg daily indefinitely (control group)
Study: 37634707
Drug: Continuing SGLT2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing SGLT2 inhibitors in patients with HF and eGFR <25 mL/min/1.73 m²
Study: 37635769
Drug: Night-time only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Night-time only subcutaneous apomorphine infusion
Study: 37635815
Drug: Induction systemic
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction systemic therapy with doublet or triplet chemotherapy plus targeted therapy
Study: 39445322
Drug: E-BPO cream,
Approvals — FDA: no, EMA: no, PMDA: no
Description: E-BPO cream, 5%
Study: 37636296
Drug: Pre- and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre- and/or postconditioning treatment in addition to conventional percutaneous coronary intervention
Study: 37637060
Drug: Interval debulking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interval debulking surgery after neoadjuvant chemotherapy (IDS/NAC)
Study: 37637501
Drug: TAE-iNKT (Transarterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAE-iNKT (Transarterial Embolization with biweekly iNKT cell infusion)
Study: 37637501
Drug: TAE (Transarterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAE (Transarterial Embolization without iNKT cell infusion)
Study: 37637850
Drug: Transcutaneous afferent
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous afferent patterned stimulation (TAPS) therapy, unsupervised at-home sessions twice daily for four weeks
Study: 37637850
Drug: Transcutaneous afferent
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous afferent patterned stimulation (TAPS) therapy
Study: 37637935
Drug: M8891 (7-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: M8891 (7-80 mg once daily in 21-day cycles)
Study: 37638077
Drug: i.v. fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. fentanyl 25 μg
Study: 37638196
Drug: Endovascular Treatment
Normalized name: Drug coated peripheral artery endovascular stent graft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular Treatment (EVT)
Study: 39648617
Drug: Atogepant 60
Normalized name: atogepant 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atogepant 60 mg once-daily
Study: 37638435
Drug: Low-dose radiation
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radiation therapy (LDRT) 24 cGy/6 fractions
Study: 37638435
Drug: Low-dose radiation
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radiation therapy (LDRT) 300 cGy/6 fractions
Study: 37638435
Drug: Sham radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham radiation therapy (0 cGy/6 fractions)
Study: 37638695
Drug: Muvalaplin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muvalaplin (30 mg to 800 mg daily for 14 days)
Study: 37638695
Drug: Muvalaplin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muvalaplin (single ascending dose of 1 mg to 800 mg)
Study: 37638695
Drug: Muvalaplin (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muvalaplin (multiple ascending dose)
Study: 37638882
Drug: Knowledge of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge of treatment options
Study: 37638882
Drug: Awareness of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Awareness of treatment options offered
Study: 37638882
Drug: Treatment goal
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment goal rankings
Study: 37638882
Drug: Variability in
Normalized name: Ferric carbonate, ferric hydroxide, ferrous hydroxide (variable mixture)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variability in treatment goal importance
Study: 37638882
Drug: Most important
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Most important treatment goal
Study: 37638968
Drug: 12-month edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month edoxaban treatment
Study: 37638968
Drug: 3-month edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-month edoxaban treatment
Study: 37639169
Drug: Patisiran 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patisiran 0.3 mg/kg intravenously every 3 weeks for 12 months
Study: 37639169
Drug: Patisiran 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patisiran 0.3 mg/kg q3w
Study: 37639259
Drug: Mavacamten (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavacamten (2.5 mg once daily for 30 weeks)
Study: 37639601
Drug: Nicotinic acetylcholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinic acetylcholine receptor agonist
Study: 37639777
Drug: Gaboxadol (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaboxadol (0.125 mg/kg to 0.24 mg/kg based on weight)
Study: 37639820
Drug: Chemotherapy or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy or oral targeted therapy
Study: 37639820
Drug: Active cancer
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active cancer treatment